Pancreatic Cancer Research

ResearcherIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'OrsolaActive in the last 2 years

Giorgio Ercolani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4334-5167; OpenAlex author ID A5020323314, A5033704234. Sources: OpenAlex.

Their work

Papers
22 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
76
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 5 papers · 2025: none · 2026: 4 papers

Papers 22

  1. Rim enhancement on imaging of pancreatic ductal adenocarcinoma: systematic review and meta-analysis of biological and prognostic values. Co-author DOI 10.1007/s11547-025-02131-7↗
  2. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  3. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  4. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  5. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2024.2485↗
  6. Local recurrence rate as quality indicator in surgery for pancreatic cancer? Last author DOI 10.1016/j.hbpd.2024.03.003↗
  7. The pan - COVID - AGICT study. The impact of COVID-19 pandemic on surgically treated pancreatic cancer patients. A multicentric Italian study. Co-author DOI 10.1016/j.suronc.2024.102081↗
  8. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. Co-author DOI 10.1097/sla.0000000000006166↗
  9. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  10. European' health care indicators and pancreatic cancer incidence and mortality: A mediation analysis of Eurostat data and Global Burden of Disease Study 2019. Last author DOI 10.1016/j.pan.2023.09.001↗
  11. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  12. Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. Last author DOI 10.1016/j.ejso.2022.04.011↗
  13. Microbiota in the Natural History of Pancreatic Cancer: From Predisposition to Therapy. Co-author DOI 10.3390/cancers15010001↗
  14. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  15. Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. Co-author DOI 10.3390/biom11081200↗
  16. Searching for novel multimodal treatments in oligometastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06718-3↗
  17. Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers … Co-author DOI 10.3390/cancers12010178↗
  18. The impact of extent of pancreatic and venous resection on survival for patients with pancreatic cancer. First author DOI 10.1016/j.hbpd.2019.06.004↗
  19. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Co-author DOI 10.3390/cancers11050663↗
  20. A comprehensive analysis on expected years of life lost due to pancreatic cancer. First author DOI 10.1016/j.pan.2016.02.005↗
  21. Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000000523↗
  22. Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array. Co-author DOI 10.3892/mmr.2015.4344↗

Closest collaborators

The 25 strongest of 76 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alessandro Cucchetti · 10 shared papers, 2016–2026 · strength 1.76
  2. Massimo Falconi · 6 shared papers, 2021–2026 · strength 1.02
  3. Stefano Crippa · 4 shared papers, 2022–2024 · strength 0.73
  4. Cecilia Binda · 3 shared papers, 2022–2026 · strength 0.64
  5. Riccardo Casadei · 5 shared papers, 2015–2024 · strength 0.59
  6. Giuseppe Malleo · 3 shared papers, 2024–2026 · strength 0.57
  7. Giulio Belfiori · 3 shared papers, 2024–2026 · strength 0.57
  8. Carlo Alberto Pacilio · 2 shared papers, 2023–2024 · strength 0.56
  9. Carlo Fabbri · 3 shared papers, 2022–2023 · strength 0.52
  10. Claudio Ricci · 4 shared papers, 2015–2024 · strength 0.51
  11. Roberto Salvia · 3 shared papers, 2021–2024 · strength 0.44
  12. Mariacristina Di Marco · 3 shared papers, 2015–2026 · strength 0.36
  13. Fabio Casciani · 2 shared papers, 2024 · strength 0.36
  14. Alessandro Ferrero · 2 shared papers, 2024 · strength 0.36
  15. Serena Langella · 2 shared papers, 2024 · strength 0.36
  16. Gabriella Lionetto Lionetto · 2 shared papers, 2024 · strength 0.36
  17. Ilario Giovanni Rapposelli · 2 shared papers, 2021–2026 · strength 0.32
  18. Matteo Renzulli · 1 shared paper, 2026 · strength 0.32
  19. Emanuela Giampalma · 1 shared paper, 2026 · strength 0.32
  20. Antonino Romeo · 3 shared papers, 2019–2021 · strength 0.29
  21. Alessandro Passardi · 3 shared papers, 2019–2021 · strength 0.29
  22. Marina Macchini · 2 shared papers, 2015–2026 · strength 0.25
  23. Mario Scartozzi · 1 shared paper, 2026 · strength 0.21
  24. Letizia Procaccio · 1 shared paper, 2026 · strength 0.21
  25. Catia Carconi · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.